Mesoblast Ltd
Company Profile
Business description
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUST: +61 396396036
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
108
Stocks News & Analysis
stocks
ASX top pick remains cheap despite weaker consumer confidence
stocks
Chart of the Week: Aussie dividend yields below 10-year average
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,144.70 | 60.50 | -0.66% |
| CAC 40 | 8,071.85 | 133.52 | -1.63% |
| DAX 40 | 25,694.67 | 630.34 | -2.39% |
| Dow JONES (US) | 51,523.06 | 1,833.06 | -3.44% |
| FTSE 100 | 10,563.72 | 218.94 | -2.03% |
| HKSE | 24,481.86 | 315.12 | -1.27% |
| NASDAQ | 24,315.00 | 1,421.52 | -5.52% |
| Nikkei 225 | 57,434.77 | 3,643.13 | -5.96% |
| NZX 50 Index | 13,998.50 | 92.47 | -0.66% |
| S&P 500 | 7,353.73 | 0.00 | 0.00% |
| S&P/ASX 200 | 9,020.80 | 44.30 | -0.49% |
| SSE Composite Index | 3,649.18 | 40.73 | -1.10% |